• Home
  • Topic
    • COVID-19
    • New Drugs
    • Oncology
    • Cardiology
    • Metabolism
    • Neuroscience
    • Autoimmune Diseases
    • Infections
    • Rare/Orphan Diseases
    • Drug Safety
  • Section
    • Pharma & Biotech
    • Regulatory
    • Clinical Trials
    • Mergers & Acquisitions
    • Research
    • In the Pipeline
  • BioPharma News
    • About Us
    • Our Team
    • Contact Us
    • Editorial Policy
    • Terms of Use
    • Privacy Policy
  • Subscribe
  • Facebook
  • Twitter
  • LinkedIn
  • Google News
Skip to content
  • Facebook
  • Twitter
  • LinkedIn
  • Google News
BioPharma News

BioPharma News

Biopharmaceutical industry analysis. Credible, reliable, equitable.

Subscribe
  • Home
  • Topic
    • COVID-19
    • New Drugs
    • Oncology
    • Cardiology
    • Metabolism
    • Neuroscience
    • Autoimmune Diseases
    • Infections
    • Rare/Orphan Diseases
    • Drug Safety
  • Section
    • Pharma & Biotech
    • Regulatory
    • Clinical Trials
    • Mergers & Acquisitions
    • Research
    • In the Pipeline
  • BioPharma News
    • About Us
    • Our Team
    • Contact Us
    • Editorial Policy
    • Terms of Use
    • Privacy Policy
  • Subscribe

Shionogi & Co.

Posted inCOVID-19, Infections, New Drugs, Regulatory

Xocova: Powerful New Japanese Pill for Coronavirus Treatment

by Nik Resovski and Timur Burkhanayev November 27, 2022December 5, 2022

Ensitrelvir by Shionogi & Co. is a highly effective antiviral drug that works just as well as Pfizer’s Paxlovid.

Paxlovid (nirmatrelvir + ritonavir)
Posted inCOVID-19, Infections, Regulatory

Paxlovid for COVID-19 Treatment. All Details

by Tanya von Reuss and Timur Burkhanayev August 24, 2022March 10, 2024

Paxlovid: treatment efficacy, “Paxlovid mouth”, COVID-19 rebound, management of Omicron variant, treatment resistance, generics, mechanism of action, price.

olorofim
Posted inClinical Trials, Infections, Rare/Orphan Diseases

Olorofim: New Antifungal Drug

by Tanya von Reuss June 9, 2022September 8, 2022

Olorophim by F2G and Shionogi & Co. is focused on invasive aspergillosis treatment.

Posted inClinical Trials, Metabolism, Neuroscience, Rare/Orphan Diseases

Redasemtide: Universal Medicine for Regeneration of Any Tissue

by Nik Resovski and Timur Burkhanayev February 12, 2022September 8, 2022

Redasemtide as a lifesaver for the most devastating diseases, including stroke, osteoarthritis, cardiomyopathy, and bullous epidermolysis.

cough
Posted inNeuroscience, New Drugs, Regulatory

Lyfnua: First Drug for Refractory or Unexplained Chronic Cough

by Mark Gubar January 25, 2022September 8, 2022

Gefapixant will reduce cough frequency, thereby improving patients’ quality of life.

Posted inInfections, New Drugs, Regulatory

Apretude: New Drug to Prevent HIV Infection

by Julia Mardi December 21, 2021September 8, 2022

Injecting cabotegravir once every two months will high effectively protect against HIV infection.

Posted inInfections, New Drugs, Regulatory

Fetroja/Fetcroja: New Cephalosporin That Bypasses All Antibiotic Resistance

by Nik Resovski December 11, 2021September 8, 2022

The antibiotic Fetroja/Fetcroja penetrates bacteria like a Trojan horse.

BioPharma News Logo
Biopharmaceutical industry analysis.
© 2025 BioPharma News Powered by Newspack Privacy Policy
  • Facebook
  • Twitter
  • LinkedIn
  • Google News
BioPharma News

Awareness and enlightenment are strengths.

BioPharma News is an amazing and trustworthy non-profit data analysis service that provides honest and objective reporting on the Pharma & Biotech industry. We would like to invite you to sign up for our weekly Newsletter to stay informed and uptodate.

Please check your inbox or spam folder for an email from [email protected] to confirm your subscription.

×